Natural product-derived therapy for Human Leukemias: Manumycin A, an antibiotic that acts as an inhibitor of farnesyltransferase (FTase), suppresses B-Cell and myeloid leukemias via up regulation of the tumor suppressor IRF4, 16/January/2016, 11.45 pm

Fish oil therapy for glucose homeostasis and TIIDM: Docosahexaenoic acid (DHA), found in fish oil and algae oil among others, increases Pax6 and insulin expression, decreases the levels of glucagon, ghrelin and Somatostatin, reduces metabolic stress, improves insulin sensitivity, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene, 16/January/2017, 11.21 pm
January 16, 2017
Natural product-derived therapy for Myocardial Infarction: Tyrosol, found in Olive oil and argan oil among others, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via up-regulation of PNUTS, 16/January/2017, 11.59 pm
January 16, 2017
Show all

Introduction: What they say

Noble laureate in Physiology/Medicine (1975) Prof. David Baltimore, from California Institute of Technology, California, USA, had reported in the July 8, 2014 issue of the Journal “Blood” that: “Dual mechanisms by which MiR-125b represses IRF4 to induce myeloid/B-cell leukemias.” 


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-derived therapy for Human Leukemias: Manumycin A, an antibiotic that acts as an inhibitor of farnesyltransferase (FTase), suppresses B-Cell and myeloid leukemias via up regulation of the tumor suppressor IRF4


From Research findings to Therapeutic opportunity:

This study suggests that Manumycin A, by increasing the expression of  its target gene, it may increase the expression of a number of tumor suppressor genes, including IRF4. Thereby, it could inhibit the progression of B-Cell and myeloid leukemias (fig. 1).

price-100

[easy_payment currency=”USD”]

Taken together, this study suggests that pharmacological formulations encompassing       Manumycin A or its analogues or Manumycin A in combination with other anticancer drugs may be used to inhibit B-Cell and myeloid leukemias.

Manumycin suppresses IRF4 expression

Figure 1 Mechanistic insight into how Manumycin A increases the expression of IRF4 to prevent cancer proliferation


Details of the research details

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How Manumycin A increases the expression of IRF4?

Amount: $ 100

For purchase and payment details, you may reach us at admin@genomediscovery.org

# Research cooperation


References:

Web: http://genomediscovery.org or newbioideas.com

CitationBoominathan, L., Natural product-derived therapy for Human Leukemias: Manumycin A, an antibiotic that acts as an inhibitor of farnesyltransferase (FTase), suppresses B-Cell and myeloid leukemias via up regulation of the tumor suppressor IRF4, 16/January/2016, 11.45 pm,  Genome-2-Bio-Medicine Discovery Center.

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.